Dr. Jifeng Feng 冯继锋
Chief Physician
Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical treatment of advanced tumors, with a focus on breast cancer, lung cancer, and malignant lymphoma.
Dr. Feng is Chief Physician and Party Secretary at Jiangsu Cancer Hospital. Dr. Feng leads key specialty disciplines and supervises master's students. Research includes two National Natural Science Foundation projects and one Jiangsu provincial project. From 2015 to 2017, Dr. Feng participated in 78 clinical trials for new anti-cancer drugs, serving as national lead PI for seven. Dr. Feng has published 43 SCI papers in the last three years and holds five patents.
Professional roles
- Vice Chair, Oncology Physicians Branch, Chinese Medical Doctor Association
- Chair, Jiangsu Provincial Committee on Cancer Prevention and Control, Jiangsu Preventive Medicine Association
- Chair, Chemotherapy Professional Committee, Jiangsu Anti-Cancer Association
- Chair, Lymphoma Professional Committee, Jiangsu Anti-Cancer Association
Name order: in Chinese the family name comes first (Feng Jifeng). Papers usually list the name as Jifeng Feng or Feng J.
Selected publications
302 papers on PubMed matched by name and affiliation; 69 as first or senior author since 2016. Most recent first- or senior-author papers:
- Med Oncol, 2025 (senior author): Retraction Note: Long noncoding RNA HULC is a novel biomarker of poor prognosis in patients with pancreatic cancer. PubMed 40153140
- Cell Biosci, 2024 (senior author): Bromodomain proteins as potential therapeutic targets for B-cell non-Hodgkin lymphoma. PubMed 39580422
- Front Oncol, 2024 (senior author): Optimal response to tislelizumab plus chemotherapy in metastatic triple-negative breast cancer: a case report and literature review. PubMed 38606104
- Cell Commun Signal, 2024 (senior author): Rolapitant treats lung cancer by targeting deubiquitinase OTUD3. PubMed 38539203
- Transl Cancer Res, 2024 (senior author): A novel gene signature related to fatty acid metabolism predicts prognosis, immune landscape, and drug sensitivity in early-stage lung squamous cell carcinoma. PubMed 38482436
- Int J Clin Pract, 2024 (senior author): Comparison of Efficacy and Safety of First-Line Treatment Options for Unresectable Stage III Non-Small Cell Lung Cancer: A Retrospective Analysis. PubMed 38375028
- J Cancer Res Clin Oncol, 2024 (senior author): Plasma cell-free DNA as a sensitive biomarker for multi-cancer detection and immunotherapy outcomes prediction. PubMed 38196018
- Anticancer Agents Med Chem, 2024 (senior author): FN-1501 Inhibits Diffuse Large B-Cell Lymphoma Tumor Growth by Inducing Cell Cycle Arrest and Apoptosis. PubMed 39229996
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion